|
Dec 9
|
Cogent Biosciences Announces Positive Initial Data from Phase 2 SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis (NonAdvSM)
|
|
Dec 7
|
Cogent Biosciences Presents New Preclinical Data Highlighting Potential Best-in-Class Potency and Selectivity of ErbB2 and PI3Kα inhibitor programs at the San Antonio Breast Cancer Symposium
|
|
Dec 4
|
Cogent Biosciences to Host Investor Webcast on December 11, 2023 at 8:00 AM ET to Review Clinical Data Being Presented at American Society of Hematology (ASH) Annual Meeting
|
|
Nov 29
|
Cogent Biosciences Announces Poster Presentations at Upcoming San Antonio Breast Cancer Symposium
|
|
Nov 27
|
Is Cogent Biosciences (NASDAQ:COGT) In A Good Position To Deliver On Growth Plans?
|